BioSpace News Archive

Business

Exact Sciences Announces Preliminary Fourth Quarter 2019 Results

Expected total revenue of $294-296M, including Screening revenue of $229-230M, an increase of 61 percent from 2018, and Precision Oncology revenue of $65-66M for period Nov. 8, 2019 through Dec. 31, 2019

January 12, 2020
·
10 min read
Business

Cutera Announces Preliminary Financial Results for Fourth Quarter and Full-Year 2019

Cutera, Inc., a leading provider of energy-based aesthetic systems for practitioners worldwide, announced certain preliminary, unaudited, financial results for the fourth quarter and year ended December 31, 2019.

January 12, 2020
·
3 min read
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

January 12, 2020
·
9 min read
Biotech Bay

Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer

LUNAR-1 liquid biopsy assay will be used to identify molecular residual disease and support its validation as a diagnostic biomarker

January 12, 2020
·
6 min read
Drug Development

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control

January 12, 2020
·
7 min read
Skyrocketing growth tipped for China Medical industry over next 5 years; Medtec China 2020 upgrades to two halls to meet market needs

According to a forecast from CIConsulting, the revenue of China’s medical equipment and manufacturing industry will reach CNY327.4 billion in 2019, the average annual compound growth rate over the next five years will be about 8.15%, and the market will reach CNY447.9 billion in 2023.

January 12, 2020
·
3 min read
Business

Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan

Mundipharma announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.

January 12, 2020
·
2 min read
Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019.

January 12, 2020
·
4 min read
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company the results of a Phase 3 study in China; the ORIENT-11 trial of Tyvyt® in combination with ALIMTA® and platinum in first-line advanced or recurrent nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement, met the predefined primary endpoint of progression-free survival in an interim analysis.

January 12, 2020
·
8 min read